filanesib
Small moleculeexperimental
Filanesib is a kinesin spindle protein (KIF11) inhibitor which has recently been proposed as a cancer treatment, specifically for multiple myeloma. — Wikipedia
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT00462358)
Timeline
Indications
Mechanism of action
- Kinesin-like protein 1INHIBITOR
Kinesin-like protein 1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CON(C)C(=O)N1N=C(c2cc(F)ccc2F)S[C@@]1(CCCN)c1ccccc1- Mol. weight
- 420.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFilanesib ↗
- ChEMBLCHEMBL2347655 ↗
Also known as
- arry 520
- arry-520
- arry-520
- arry-520
- arry-520
- filanesib
- filanesib
- filanesib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02384083 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Array BioPharma, Celgene, PETHEMA Foundation |
| NCT02092922 | Phase 2 | May 1, 2014 | Array BioPharma |
| NCT01989325 | Phase 2 | Nov 1, 2013 | Array BioPharma |
| NCT01372540 | Phase 1 | Feb 1, 2012 | Array BioPharma, Onyx, University of Texas at Houston |
| NCT01248923 | Phase 1 | Dec 1, 2010 | Array BioPharma |
| NCT00821249 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2009 | Array BioPharma |
| NCT00637052 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2008 | Array BioPharma |
| NCT00462358 | Phase 1 | Apr 1, 2007 | Array BioPharma |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Array BioPharma | For profit | 8 | 6 | 2 | 2007 |
| Celgene | For profit | 1 | 0 | 1 | 2015 |
| Onyx | For profit | 1 | 0 | 1 | 2012 |
| PETHEMA Foundation | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2012 |
5 organizations
Page 1 / 1